Mesenchymal Stem Cell– tag –
-
Japan Launches Akougo (Vandefitemcel): A Groundbreaking Cell Therapy Revolutionizing Chronic Motor Impairment Post-TBI
Reddit (引用元: 日刊工業新聞) Japan Overview SanBio has introduced Akougo (Vandefitemcel) in Japan, a pioneering cell therapy designed to address chronic motor impairment following traumatic brain injury (TBI). This innovative regenerati... -
Ernexa Therapeutics Accelerates iPSC-Derived MSC Manufacturing with Japan JEAP Selection, Highlighting Japan’s CDMO Ecosystem as Key
Clinical Leader USA Overview Ernexa Therapeutics has been selected for Japan's Entry Acceleration Program (JEAP), gaining a critical opportunity to advance its induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (iMSC) pla... -
BioProcess International Reports on Mesenchymal Stem Cell (MSC) Large-Volume Manufacturing Challenges and Corning HYPERStack™ Contribution
BioProcess International USA Overview BioProcess International reported on the challenges and progress in large-volume manufacturing of mesenchymal stem cells (MSCs). The approval of two iPSC-derived therapies in Japan indicates growing ... -
Cell Therapy Weekly: uniQure Plans BLA Submission for Huntington’s Gene Therapy AMT-130; Ernexa Prepares IND for iMSC, Autolus Reports Early Phase I Data for SLE CAR-T
Cell & Gene Therapy Insights USA Overview uniQure plans to submit a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington's disease, in Q3 2026, based on three-year Phase I/II data. Ernexa Therapeutics has comple... -
Cynata Therapeutics to Announce Phase 3 iPSC-Derived MSC Results for Knee Osteoarthritis in June; Acute GVHD Phase 2 Nears Completion
Regen Report Australia Overview Cynata Therapeutics is set to release top-line results from its Phase 3 clinical trial, 'STOP-OA,' for knee osteoarthritis (KOA) using iPSC-derived mesenchymal stem cells (iPSC-MSC). The KOA trial database... -
Cynata Therapeutics Anticipates Announcing iPSC-MSC Clinical Results for Knee Osteoarthritis Phase 3 and Acute GvHD Phase 2 Trials Soon
Regen Report Australia Overview Australian cell therapy company Cynata Therapeutics has announced it will release results from two pivotal clinical trials using its iPSC-derived mesenchymal stem cells (iPSC-MSC) within months. These incl... -
Terumo BCT and Steminent Partner to Automate Mesenchymal Stem Cell Manufacturing for Late-Stage Clinical Commercialization
Terumo Blood and Cell Technologies Taiwan Overview Terumo Blood and Cell Technologies (Terumo BCT) and Taipei-based Steminent Biotherapeutics Inc. have announced a strategic collaboration to accelerate late-stage manufacturing readiness ... -
CellFiber and Locus Cell Establish Commercial-Scale Manufacturing for Human Umbilical Cord-Derived Mesenchymal Stem Cells Using Advanced 3D Culture Technology
PR TIMES Japan Overview Japan's CellFiber and its Taiwanese partner Locus Cell have successfully established a commercial-scale manufacturing process for human umbilical cord-derived mesenchymal stem cells (UC-MSC) utilizing the innovati... -
CDMO Sector Sees Strategic Expansions: Andelyn Biosciences Launches LVV Platform, Made Scientific Partners with RoosterBio
DCAT Value Chain Insights USA Overview The biopharmaceutical contract development and manufacturing (CDMO) sector is experiencing significant strategic advancements, with Andelyn Biosciences unveiling its 'LVV curator platform' for stand... -
Locus Cell Establishes Large-Scale Manufacturing Process for Human Umbilical Cord Mesenchymal Stem Cells Using CellFiber® Technology
PR Times Japan Overview Locus Cell Inc., in collaboration with CellFiber Inc., has announced the successful establishment of a large-scale, high-efficiency manufacturing process for human umbilical cord-derived mesenchymal stem cells (UC...
